the Delphi Panel, John W. Upham, Chantal Le Lievre, David J. Jackson, Matthew Masoli, Michael E. Wechsler, David B. Price, Adel Mansur, Aikaterini Detoraki, Alan Altraja, Alan James, Alexandra Nanzer-Kelly, Andréanne Côté, Andrew Menzies-Gow, Andriana Papaioannou, Anne Maree Cheffins, Arnaud Bourdin, Bassam Mahboub, Brian Lipworth, Carlos Andrés Celis-Preciado & 31 more Carlos Torres-Duque, Caterina Bucca, Celeste Porsbjerg, Charlotte Ulrik, Chris Corrigan, Christian Taube, Claude Farah, Constance Katelaris, David Langton, Dermot Ryan, Désirée Larenas-Linnemann, Eleftherios Zervas, Enrico Heffler, Flavia Hoyte, Francesca Puggioni, George Christoff, Giorgio Walter Canonica, Giovanna Elisiana Carpagnano, Giuseppe Guida, Gregory Katsoulotos, Guy Brusselle, Hitashi Rupani, Hubertus Jersmann, Ian Clifton, Jaideep Dhariwal, James Fingleton, Jane Duke, Janet Rimmer, Jo Douglass, Maria Conte, Paul Pfeffer
Funding Information:
Conflicts of interest: J.W. Upham reports personal fees from AstraZeneca, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, and Novartis, outside the submitted work. D.J. Jackson reports personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Napp, Chiesi, and Novartis; and grants from AstraZeneca , outside the submitted work. M. Masoli reports personal fees from Novartis and AstraZeneca, outside the submitted work. M.E. Wechsler reports grants and personal fees from Novartis , Sanofi , and Cohero Health ; personal fees from Regeneron, Genentech, Sentien, Restorbio, Equillium, and Genzyme; grants, personal fees, and nonfinancial support from Teva and AstraZeneca ; personal fees and nonfinancial support from Boehringer Ingelheim ; and personal fees from GSK, outside the submitted work. D.B. Price reports grants from AKL Research and Development Ltd , British Lung Foundation , Respiratory Effectiveness Group , and UK National Health Service ; grants and personal fees from AstraZeneca , Boehringer Ingelheim , Chiesi , Mylan , Novartis , Regeneron Pharmaceuticals , Sanofi Genzyme , Theravance , Zentiva (Sanofi Generics); personal fees from Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Airway Vista Secretariat, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L, Talos Health Solutions, and WebMD Global LLC, outside the submitted work; nonfinancial support from Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and 5% shareholding in Timestamp, which develops adherence monitoring technology. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This project was supported by in kind contributions from the Observational and Pragmatic Research Institute and the University of Queensland Faculty of Medicine . No pharmaceutical companies were involved in the study design or execution.
Funding Information:
This project was supported by in kind contributions from the Observational and Pragmatic Research Institute and the University of Queensland Faculty of Medicine. No pharmaceutical companies were involved in the study design or execution.Conflicts of interest: J.W. Upham reports personal fees from AstraZeneca, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, and Novartis, outside the submitted work. D.J. Jackson reports personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Napp, Chiesi, and Novartis; and grants from AstraZeneca, outside the submitted work. M. Masoli reports personal fees from Novartis and AstraZeneca, outside the submitted work. M.E. Wechsler reports grants and personal fees from Novartis, Sanofi, and Cohero Health; personal fees from Regeneron, Genentech, Sentien, Restorbio, Equillium, and Genzyme; grants, personal fees, and nonfinancial support from Teva and AstraZeneca; personal fees and nonfinancial support from Boehringer Ingelheim; and personal fees from GSK, outside the submitted work. D.B. Price reports grants from AKL Research and Development Ltd, British Lung Foundation, Respiratory Effectiveness Group, and UK National Health Service; grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Theravance, Zentiva (Sanofi Generics); personal fees from Cipla, GlaxoSmithKline, Kyorin, Merck, Mundipharma, Airway Vista Secretariat, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc, Strategic North Limited, Synapse Research Management Partners S.L, Talos Health Solutions, and WebMD Global LLC, outside the submitted work; nonfinancial support from Efficacy and Mechanism Evaluation programme and Health Technology Assessment; and stock/stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and 5% shareholding in Timestamp, which develops adherence monitoring technology. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2021 American Academy of Allergy, Asthma & Immunology